The UK's National Health Service has issued guidelines for the company's ExAblate focused ultrasound device for the removal of uterine fibroids.
Elbit Medical Technologies Ltd. (TASE:EMTC) subsidiary InSightec Image Guided Treatment Ltd. has obtained guidelines from the UK's National Health Service's National Institute for Health and Clinical Excellence (NICE) for use of the company's ExAblate focused ultrasound device for the removal of uterine fibroids.
The guidelines are based on scores of NICE studies on more than 1,000 procedures using the technology. Insightec believes that the guidelines will help the technology become more available for women in the UK and worldwide, and will help in the obtaining of insurance indemnification for the procedure.
Elbit Medical owns 62% of Insightec. Other investors include GE Healthcare.
Published by Globes [online], Israel business news - www.globes-online.com - on November 27, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011